Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes. The agreement also will settle kickback charges related to the nation's largest long-term care pharmacy, Omnicare.
Two big reactions hit me when news of Johnson & Johnson's $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it's paying out and, second, some individual probably is going to cash a nice paycheck for bringing it all to light.
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes, the U.S. Department of Justice announced Monday. The agreement is one the largest ever of its kind, and will also settle charges that the companies paid kickbacks to the nation's largest long-term care pharmacy, Omnicare.
Omnicare, the nation's largest provider of long-term care pharmacy services, has agreed to pay $120 million to settle a False Claims Act lawsuit over Medicare Part A drug pricing, the company announced Wednesday. The settlement likely is one of the largest in a whistleblower case in which the government did not intervene, according to Frederick Morgan, one of Gale's attorneys at the firm Morgan Verkamp LLC.
Omnicare, the nation's largest long-term care pharmaceutical services provider, is positioned to be successful as insurance coverage expands under the Affordable Care Act, according to CEO John Workman.
Two former nursing home executives have agreed to pay $5 million to settle a whistleblower lawsuit involving long-term care pharmacy giant Omnicare Inc., according to the Chicago Tribune.
Kindred Healthcare will split with PharMerica and instead partner with Omnicare in 2014, marking a significant change in the landscape of long-term care pharmacy services providers.
A whistleblower who alleges Omnicare Inc. paid kickbacks to nursing homes did not violate the False Claims Act, a judge has ruled.
Two nursing home operators are set to stand trial to face whistleblower allegations that Omnicare Inc. paid them kickbacks during its purchase of Total Pharmacy.
An Illinois federal judge approved the dismissal of a whistleblower lawsuit against Omnicare, following a settlement agreement on July 9, according to local media reports.
Kindred Healthcare will split with pharmacy partner PharMerica and join forces with Omnicare at the end of 2013, according to documents filed with the Securities and Exchange Commission.
Major long-term care provider Kindred Healthcare will split with its current pharmacy partner, PharMerica, and team with the sector's largest pharmacy, Omnicare, at the end of 2013, according to documents filed with the Securities and Exchange Commission.
Omnicare has failed to disqualify a whistleblower who alleges the long-term care pharmacy paid kickbacks to nursing homes, ruled a district court judge.
Long-term care pharmacy Omnicare will not face charges that it engaged in "nationwide" Medicare fraud for off-label antipsychotics prescriptions, a federal judge recently ruled. However, the pharmacy still faces more limited False Claims Act charges over billing for antipsychotic drugs allegedly used for dementia care.
Biotechnology company Amgen will pay $24.9 million in a settlement over whistleblower allegations that the company paid kickbacks to long-term care pharmacies to increase the use of an anemia drug in nursing homes.
MDI Achieve announced that MatrixCare is now integrated with several leading pharmacy service firms. These include Omnicare, PharMerica, and FrameworkLTC.
With more vendors targeting the hospice market, two drug giants appear ready to face off. Walgreens left the institutional-pharmacy business in 2010, of which hospice pharmacy is a part, in a deal with Omnicare. Walgreens traded the unit for Omnicare's home-infusion business. Since then, Omnicare has been the market leader for hospice drugs. So why the strategy change for Walgreens?
The parent company of Golden Living officially launched AlixaRx with predictions it could become a $250 million per year business within 18 months.
Executives tied to one of the nation's largest nursing home chains say a new institutional pharmacy model they unveiled this week could soon become the market's No. 3 player. The parent group of Golden Living officially launched AlixaRx this week with predictions it could become a $250 million per year business within 18 months.
The headlines were big. Really big. And they involved a long-term care corporate giant settling yet another lawsuit. But they didn't tell the story I really wanted to know about. And that you probably want to know about, too.
Omnicare agreed to settle over claims it provided a kickback when it bought Total Pharmacy services LLC in 2004. Terms of the deal were not released.
Long-term care pharmacy provider Omnicare has agreed to pay the government $50 million to settle charges that it illegally dispensed controlled medications to long-term care residents.
Omnicare has officially ended its attempt to absorb PharMerica Corp. The reversal comes less than a month after federal regulators attempted to block the deal. Officials said the merger would have created an institutional pharmacy company that reaches nearly 60% of the nation's nursing home beds. PharMerica has repeatedly tried to prevent the takeover since it was announced last year. PharMerica countered that the offer was insufficient and was unlikely to survive antitrust scrutiny.
Leading long-term care pharmacy provider Omnicare, which announced this week that it has ended its efforts to takeover competitor PharMerica, posted a profit in the fourth quarter.
Omnicare announced Monday that it is extending its offer to purchase all outstanding shares of rival PharMerica for $15 per share to Jan. 20. The original offer was scheduled to expire Dec. 2.
Maryland and North Carolina are among several states set to receive a portion of the settlement stemming from a nursing home company kickback case.
A proposed regulation that would require nursing homes to hire independent pharmacists to oversee residents' medication plan regimens could have a huge impact on pharmacy services suppliers such as Omnicare and PharMerica.
Omnicare has filed a lawsuit in hopes of making PharMerica accept a $440 million purchase offer and halt a poison pill anti-takeover defense.
Omnicare's top management decided private negotiations with their counterparts at takeover target PharMerica were not working. So on Tuesday, Omnicare went public with an announced $15 per share bid for the company. The proposed deal would involve the No. 1 institutional pharmacy provider purchasing the No. 2 for $715 million, according to an Omnicare announcement.
Omnicare, the biggest institutional pharmacy provider in the long-term care sector, publicly announced a $715 million bid for top rival PharMerica on Tuesday. Dissatisfied with the outcome of behind-doors talks over the past four months, Omnicare leaders decided to take their case directly to PharMerica board members.